NEW YORK, NY
4 risk indicators measuring financial stability and operational resilience
Sign in with your work email to view Tuckman-Chang indicators
Sign In — Free (10 views/day)SANDERS TRI-INSTITUTIONAL THERAPEUTICS DISCOVERY INSTITUTE INC CO WEILL CORNEL, founded in 2013, is a mid-sized nonprofit in the Medical Research sector that reported $16.6M in total revenue in fiscal year 2024. Revenue decreased 11% compared to the prior year.
TO FURTHER AND IMPROVE HEALTH AND THE DIAGNOSIS, PREVENTION AND TREATMENT OF DISEASE THROUGH RESEARCH, GENERATE INNOVATIVE PROOF-OF-CONCEPT STUDIES, AND ADVANCE THE SCIENTIFIC ACTIVITIES OF THE CONTROLLING INSTITUTIONS. (CONTINUED ON SCHEDULE O)THE SANDERS TRI-INSTITUTIONAL THERAPEUTICS DISCOVERY INSTITUTE, INC. WAS ORGANIZED AND IS OPERATED AS AN INDEPENDENT, NON-PROFIT CORPORATION, CONTROLLED BY LEADING NOT-FOR-PROFIT ACADEMIC, MEDICAL AND RESEARCH INSTITUTIONS, TO FURTHER AND IMPROVE HEALTH AND THE DIAGNOSIS, PREVENTION AND TREATMENT OF DISEASE THROUGH TRANSLATIONAL RESEARCH, GENERATE INNOVATIVE PROOF-OF-CONCEPT STUDIES, AND ADVANCE THE SCIENTIFIC ACTIVITIES OF THE CONTROLLING INSTITUTIONS (MEMORIAL SLOAN KETTERING CANCER CENTER, THE ROCKEFELLER UNIVERSITY, AND WEILL CORNELL MEDICAL COLLEGE) FACULTY, FELLOWS AND STUDENTS IN ASPECTS OF TRANSLATIONAL RESEARCH, CHEMISTRY, PHARMACOLOGY, AND DRUG DISCOVERY.
THE SANDERS TRI-INSTITUTIONAL THERAPEUTICS DISCOVERY INSTITUTE, A PARTNERSHIP AMONG THREE WORLD-RENOWNED SCIENTIFIC AND MEDICAL INSTITUTIONS, WORKS TO MORE EFFECTIVELY DEVELOP THERAPEUTICS THAT ARISE...
THE SANDERS TRI-INSTITUTIONAL THERAPEUTICS DISCOVERY INSTITUTE, A PARTNERSHIP AMONG THREE WORLD-RENOWNED SCIENTIFIC AND MEDICAL INSTITUTIONS, WORKS TO MORE EFFECTIVELY DEVELOP THERAPEUTICS THAT ARISE FROM DISCOVERIES MADE IN BASIC SCIENCE LABS. WITH A FOCUS ON EARLY-STAGE DRUG DISCOVERY, THE INSTITUTE PROVIDES EXPERTISE IN MEDICINAL CHEMISTRY AND COMPOUND SCREENING, AND CONDUCTS PROOF OF CONCEPT STUDIES NEEDED TO DEMONSTRATE THAT DRUG CANDIDATES CAN SUCCESSFULLY ALTER THE COURSE OF A DISEASE. SPECIFIC RESEARCH PROJECTS FOCUS ON ALZHEIMERS DISEASE, SICKLE CELL, OSTEOPOROSIS, LYSOSOMAL, LIPID DEPOSITS, PARKINSON'S AND BASAL CELL CARCINOMA.
THE INSTITUTE FACILITATES MORE EFFICIENT SHARING OF CORE FACILITIES BETWEEN THE THREE PARTNER INSTITUTIONS AND FORMS INDUSTRY PARTNERSHIPS WITH PHARMACEUTICAL AND BIOTECH COMPANIES TO FURTHER ADVANCE...
THE INSTITUTE FACILITATES MORE EFFICIENT SHARING OF CORE FACILITIES BETWEEN THE THREE PARTNER INSTITUTIONS AND FORMS INDUSTRY PARTNERSHIPS WITH PHARMACEUTICAL AND BIOTECH COMPANIES TO FURTHER ADVANCE DRUG RESEARCH. IT SEEKS TO CREATE INTELLECTUAL PROPERTY THAT CAN BE FURTHER DEVELOPED BY AN OPEN FIELD OF INDUSTRY COLLABORATORS. THE MAJORITY OF SUCH SERVICES RELATE TO MEDICINAL CHEMISTRY SUPPORT.
Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency
Sign in to view Trantor Score and financial metrics
Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)
Sign In — Free (10 views/day)| 2024 | 2023 | Change | |
|---|---|---|---|
| Revenue | $16,577,142 | $18,703,204 | -0.1% |
| Expenses | $16,577,142 | $18,703,204 | -0.1% |
| Net Income | $0 | $0 | N/A |
Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics
Financial Distress Indicator
Liquidity & Cash Position
Sign in to view all financial metrics
Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics
Sign In| Name | Title | Hours/Week | Role | Reportable Comp | Other Comp | Total |
|---|---|---|---|---|---|---|
| SELWYN VICKERS MD | BOARD MEMBER | 0.50 |
Director
|
$0 | $342,150 | $6,979,162 |
| RICHARD P LIFTON MD PHD | BOARD MEMBER | 0.50 |
Director
|
$0 | $285,349 | $1,593,942 |
| ROBERT HARRINGTON MD | BOARD MEMBER | 0.50 |
Director
|
$0 | $43,901 | $2,710,554 |
| BARRY COLLER MD | BOARD MEMBER | 0.50 |
Director
|
$0 | $123,955 | $840,772 |
| BARBARA HEMPSTEAD MD | BOARD MEMBER | 0.50 |
Director
|
$0 | $50,274 | $860,912 |
| DAVID SCHEINBERG MD PHD | BOARD MEMBER | 0.50 |
Director
|
$0 | $71,956 | $757,643 |
| CARL NATHAN MD | BOARD MEMBER | 0.50 |
Director
|
$0 | $68,608 | $693,861 |
| NATHANIEL HEINTZ PHD | BOARD MEMBER | 0.50 |
Director
|
$0 | $138,395 | $683,784 |
| DEREK TAN PHD | BOARD MEMBER | 0.50 |
Director
|
$0 | $85,209 | $576,024 |
| PETER T MEINKE PHD | SANDERS DIRECTOR | 40.00 |
Officer
|
$627,542 | $68,608 | $696,150 |
| MICHAEL P VITALE | TREASURER | 0.50 |
Officer
|
$0 | $144,581 | $594,046 |
| MANUEL BACA | VICE PRESIDENT, BIOLOGICS | 40.00 |
Highest
|
$403,018 | $71,836 | $474,854 |
| NIGEL LIVERTON PHD | VICE PRESIDENT, CHEMISTRY | 40.00 |
Highest
|
$290,336 | $61,066 | $351,402 |
| PAUL BALDERES | SR. DIRECTOR | 40.00 |
Highest
|
$280,506 | $61,100 | $341,606 |
| PATRICIA AHA | VICE PRESIDENT, OPRATIONS | 40.00 |
Highest
|
$300,813 | $60,121 | $360,934 |
| SANDRA LORBER | VICE PRESIDENT, FINANCE | 40.00 |
Highest
|
$255,246 | $47,104 | $302,350 |
| Year | Revenue | Expenses | Assets | Net Income |
|---|---|---|---|---|
| 2024 | $16,577,142 | $16,577,142 | $7,307,418 | No data |
| 2023 | $18,703,204 | $18,703,204 | $7,953,486 | No data |
| 2022 | $17,034,275 | $17,034,275 | $8,782,111 | No data |
| 2021 | $16,905,997 | $16,905,997 | $5,819,394 | No data |
| 2020 | $16,570,714 | $16,832,694 | $3,922,902 | $-261,980 |
| 2019 | $18,048,093 | $18,394,143 | $5,948,211 | $-346,050 |
| 2018 | $20,132,913 | $20,380,760 | $8,198,806 | $-247,847 |
Compare SANDERS TRI-INSTITUTIONAL THERAPEUTICS DISCOVERY INSTITUTE INC CO WEILL CORNEL with other nonprofits in New York and across the country.